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Forum Original Research Communication
Nerve Injection of Viral Vectors Efficiently
Transfers Transgenes into Motor Neurons
and Delivers RNAi Therapy Against ALS
Rui Wu,1 Hongyan Wang,1 Xugang Xia,1,5 Hongxia Zhou,1,5 Chunyan Liu,4
Maria Castro,4 and Zuoshang Xu1–3
Abstract
RNA interference (RNAi) mediates sequence-specific gene silencing, which can be harnessed to silencing disease-
causing genes for therapy. Particularly suitable diseases are those caused by dominant, gain-of-function type of
gene mutations. In these diseases, the mutant gene generates a mutant protein or RNA product, which possesses
toxic properties that harm cells. By silencing the mutant gene, the toxicity can be lessened because the amount of
the toxic product is lowered in cells. In this report, we tested RNAi therapy in a mouse model for amyotrophic
lateral sclerosis (ALS), which causesmotor neuron degeneration, paralysis, and death.We used a transgenicmodel
that overexpresses mutant Cu, Zn superoxide dismutase (SOD1G93A), which causes ALS by a gained toxic
property. We delivered RNAi using recombinant adenovirus (RAd) and adeno-associated virus serotype 2
(AAV2). We compared the efficiency of RNAi delivery between injecting the viral vectors into muscle and into
nerve, and found that nerve injetion is more efficient in delivering RNAi to motor neurons. Based on this data, we
conducted therapeutic trials in the mouse model and found that nerve injection of RAd, but not AAV2, at the
disease onset had a modest therapeutic efficacy. These results highlight the potential and the challenges in
delivering RNAi therapy by gene therepy. Antioxid. Redox Signal. 11, 1523–1534.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastatingneurodegenerative disease that causes motor neuron
degeneration, paralysis, and death. Approximately 10% of
ALS cases are familial and 90% are sporadic. Gene mutations
are known to underlie familial ALS. The genes where muta-
tions cause familial ALS include Cu, Zn superoxide dismutase
(SOD1), Alsin, senataxin, dynactin, VAMP-associated protein
B (VAPB), and TARDNAbinding protein 43KD (TDP-43) (25,
37, 47). Mutations in all these genes except Alsin are domi-
nantly inherited. In contrast to the familial cases, no obvious
cause is known for sporadic ALS. However, recent studies
have discovered TDP-43 as a prominent component in the
ubiquitin-positive intracellular inclusions in sporadic ALS
(2, 36), thus suggesting that TDP-43 is involved in the path-
ogenesis of sporadic ALS.
Mutations in the SOD1 gene were the first discovered ge-
netic cause for ALS and they cause *20% of familial ALS
cases (37). In the past 16 years following this discovery, much
progress has been made in our understanding of the mecha-
nism whereby the mutant SOD1 causes this disease (5).
Among the most important findings is the proof that mutant
SOD1 causes motor neuron degeneration by a gain of a toxic
property rather than a loss of the enzymatic function of
SOD1. First, there is no correlation between the retention of
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the enzyme activity and the disease-causing propensity in the
SOD1 mutants. While some mutations retain normal levels of
superoxide dismutation activity, others lose almost all the
enzyme activity (8). In addition, the presence of mutant en-
zyme does not affect the activity and stability of the normal
enzyme despite the formation of mutant-wild type hetero-
dimer (7). Second, transgenic mice expressing the mutant
SOD1 develop motor neuron degeneration and ALS without
lowering the level of superoxide dismutase activity (19, 57).
Third, neither overexpression of the wild-type SOD1 nor de-
letion of the SOD1 gene leads to ALS in mice (19, 41, 57),
indicating that alteration in normal SOD1 activity is not a
direct cause of this disease. Fourth, overexpression of wild-
type SOD1 does not alleviate, but instead, accelerates the
disease; and knockout of the endogenous SOD1 does not
significantly alter the course of the disease (10, 14, 23), indi-
cating that the level of the superoxide dismutase activity is not
related to the pathogenesis of ALS.
Since a toxic property in the mutant SOD1 causes motor
neuron degeneration, we can predict that the higher the mu-
tant protein expression, the stronger the toxicity, and conse-
quently, the more severe the disease. Indeed, in different
transgenic lines that express mutant SOD1, the higher the
expression levels, the more severe the disease, as manifested
by earlier disease onset and more rapid disease progression
(12, 55, 57). With this knowledge, we can conclude that low-
ering the mutant SOD1 expression will be therapeutic and
RNA interference (RNAi) may be harnessed for silencing the
mutant SOD1 expression (16).
RNAi is a widely conserved eukaryotic function (35).
Triggered in cells by double-stranded RNA (dsRNA), RNAi
destroys the target RNA that shares sequence homology with
the dsRNA. The main steps of the RNAi mechanism can be
simplified as the following steps (Fig. 1): First, Dicer, an
enzyme of the RNase III family, initiates ATP-dependent
fragmentation of long dsRNA into 21–25 nucleotide double-
FIG. 1. RNAi therapeutic strategies:
(1) siRNA may be delivered directly to
the CNS to silence disease genes; (2)
Pol III constructs synthesizing shRNA;
or (3) Pol II constructs synthesizing
miRNA can be placed in viral vectors
and delivered into the CNS cells for
long-term silencing of disease genes.
See text for description of the different
strategies and the RNAi mechanism.
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stranded fragments, termed small interfering RNAs (siRNAs).
Second, the siRNA duplexes bind with proteins Dicer and
TRBP (or R2D2 for invertebrates), which facilitate the forma-
tion of a siRNA=multi-protein complex called RISC loading
complex (RLC). Third, the siRNA duplex in RLC unwinds,
which involves the protein Ago2 to cleave the passenger
strand) to form an active RNA-induced silencing complex
(RISC) that contains a single-stranded RNA (called the guide
strand). Fourth, the RISC recognizes the target RNA by
Watson–Crick base pairing with the guide strand and cleaves
the target RNA. Finally, the RISC releases its cleaved product
and goes on to catalyze a new cycle of target recognition and
cleavage (39, 50).
In differentiated mammalian cells, long dsRNA activates
RNA-dependent protein kinase PKR and type I interferon
response, which leads to a nonspecific global translation de-
pression and apoptosis (18). However, this nonspecific reac-
tion can be circumvented by introduction of synthetic siRNA
(11, 17), which can go into the RNAi pathway similar to the
siRNAs produced from long dsRNA (Fig. 1, #1). Alter-
natively, RNAi may be triggered by a short hairpin RNA
(shRNA) synthesized by a Pol III promoter (Fig. 1, #2) or by a
microRNA (miRNA) that can be synthesized by either a Pol II
or Pol III promoter (Fig. 1, #3) (9, 44). The shRNA is a single-
stranded RNA folded into a simple hairpin, composed of a
perfectly base-paired stem of 21 to 23 nt and a loop. It is
synthesized by a Pol III promoter (e.g., U6) as in the nucleus
(44). In contrast, the miRNA is synthesized as a long tran-
script, called primary miRNA (pri-miRNA) (27). The pri-
miRNA need to be processed by RNase III enzyme Drosha
and its partner DGCR8 (or Pasha in invertebrates) to form
precursor miRNA (pre-miRNA), which is *70 nt long and
folds into a hairpin structure composed of an imperfectly
base-paired stem and a loop. The pre-miRNA then shares
the same downstream processing pathway with the shRNA.
Both are exported by exportin 5=RAN-GTP from the nucleus
to the cytoplasm, where they are further processed to form a
single-stranded miRNA or siRNA. This processing step is
tightly coupled with loading the guide strand of miRNA or
siRNA into the RISC, which is capable of either cleaving the
target RNA if the target perfectly complements the miRNA in
sequence, or mediating translational gene silencing if the
miRNA mismatches the target RNA at multiple base-pairs
(Fig. 1).
Because RISC recognizes its target by Watson–Crick base
pairing with the guide strand of the siRNA, destruction of
the target RNA can be specific (43). This property of RNAi can
be harnessed to target specific mRNA species for destruction,
and therefore, to silence the expression of the toxic protein
encoded by the mRNA for therapy. Thus far, RNAi therapy
for CNS diseases has been delivered by direct administration
of synthetic siRNA or genes that encode shRNA or miRNA
using viral vectors. Both delivery methods have shown ther-
apeutic efficacy in animal models for neurodegenerative dis-
eases, and thus, are potential therapeutic strategies for
humans (15, 20, 45, 54, 58).
The viral delivery method (gene therapy) delivers trans-
genes that are composed of a promoter and a desired trans-
gene cassette to the CNS cells. In recent years, viral vector
technology for gene delivery into the brain has improved
substantially (33, 42, 52). A sustained expression extending
beyond 12 months has been achieved using recombinant
adenovirus (RAd)-, lentivirus-, adeno-associated virus
(AAV)-, and herpes simplex-1 virus-derived vectors in animal
studies (32). Viral vector systems, including both adenovirus
and AAV, have been developed to the point where clinical
gene therapy for brain diseases is now possible for both acute
and chronic central nervous system pathologies. Taking ad-
vantage of these viral vectors, several groups have tested viral
delivery of RNAi therapy for neurological diseases. These
tests have shown efficacy in models for polyglutamine dis-
eases, Alzheimer disease, and ALS (13).
In these studies, two transgenes were incorporated into
AAV or lentiviral vectors. One transgene expressed a marker
gene (e.g., EGFP) driven by a Pol II promoter (e.g., CMV) and
the other expressed a shRNA driven by a Pol III promoter
(e.g., U6). The marker gene provided an indicator as to effi-
ciency with which the transgene is delivered. The shRNA si-
lences the expression of the mutated disease gene or a gene
that is in the disease pathway. In the cases of polyglutamine
diseases and Alzheimer disease, the viral vectors were di-
rectly injected into the relevant disease areas in the brain.
However, in treating ALS, the limited spread of virus presents
a particular challenge for administering the virus to wide
groups of motor neurons distributed along the spinal cord
and in the motor cortex. Injection into a single or a few spots
can only cover a small fraction of motor neurons that are
degenerating (Fig. 2A). Indeed, injection of a lentivirus de-
livering RNAi against human SOD1 into the spinal cord of an
ALS mouse model led to a local functional improvement but
no extension of survival (40).
Because of the limitation in injecting the viral vector di-
rectly into the CNS, other groups have injected the virus into
muscles (Fig. 2B). These experiments have demonstrated that
some virus such as adenovirus, AAV2, and Rabies glyco-
protein-pseudotyped lentivirus can be taken up by the nerve
terminals and retrogradely transported to the spinal cord
motor neurons (3, 26, 34). However, because eachmuscle only
receives a small number of axonal projections, injection of
many muscles were required to cover multiple motor neuron
pools. Because of the large tissue mass of the muscles, these
FIG. 2. A schematic illustration of different methods of
administering viral vectors for delivering RNAi to spinal
motor neurons: (A) direct spinal cord injection, (B) muscle
injection, and (C) nerve injection. Different colors mark the
different motor neuron pools that innervate different mus-
cles. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this
article at www.liebertonline.com=ars).
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injections also require relatively large doses of the virus.
Perhaps to reduce the required dose, Ralph and colleagues
injected a lentivirus delivering RNAi against mutant SOD1
into the muscles in 7-day-old mice, where muscle mass is
small and immune response underdeveloped. They observed
retrograde transport of the virus and the transgene expres-
sion. This treatment resulted in a large extension (*70%) in
lifespan of the mutant SOD1 mouse model (38). This is an
encouraging result for RNAi therapy but the treatment may
not be practical in humans. Administration of lentivirus to
adult humans in muscles throughout the whole body will
require even larger doses of virus, which will not only in-
crease the cost, but also put the patient at risk due to untoward
side effects, including immune responses, transduction of ir-
relevant cells (e.g., germline cells), and the potential to cause
insertion mutagenesis and neoplasia formation (28). In addi-
tion, it was unclear from this experiment whether silencing of
mutant SOD1 at the disease onset will be effective, because the
therapywas administrated long before the disease onset in the
mousemodel. In order to improve the delivery of viral vectors
to motor neurons, we administered viral vectors by nerve
injection.
Materials and Methods
Construction and production of RAd and AAV2 vectors
To generate the RAd=U6-shR-SOD1=CMV-EGFP vector,
the CMV promoter and enhanced green fluorescent fragment
(CMV-EGFP) were cut from pcDNA-EGFP and inserted into
XhoI and EcoRV sites of pDE1sp1A (Microbix Biosystems,
Inc., Toronto, Ontario, Canada). This generates the plasmid
pDE1sp1A=CMV-EGFP. The U6-shRNA expression cassette
was then cut from pBSENU6-shRNA (63) and inserted into
XhoI and PmeI sites of pDE1sp1A=CMV-EGFP. The
RAd=CMV-EGFP=U6-blank was generated using similar
method except without the shRNA. The RAd that was used
for nerve injection was produced according to our previously
published protocol (46). Briefly, vectors were scaled up by
infecting human embryonic kidney HEK 293 cells with a
multiplicity of infection of three plaque-forming units
(pfu)=cell of vector seed stock. The cells were harvested 48 h
later, lysed with 5% deoxycholate and deoxyribonulease I,
and the RAd were purified by ultracentrifugation over two
cesium chloride step gradients. Vectors were titered in tripli-
cate by end-point dilution cytopathic effect assay and
screened for the presence of replication-competent adenovi-
rus (RCA) and for lipopolysaccharide (LPS) contamination
(Cambrex, East Rutherford, NJ). Vector preparations were
free from RCA and LPS contamination.
To generate the AAV2=U6–shR–SOD1=CMV–EGFP, the
U6-shRNA expression cassette was cut from pBSENU6-
shRNA (63) and inserted into XhoI site of pcDNA-EGFP to
generate the U6–shRNA=CMV–EGFP plasmid. The CMV–
EGFP=U6–shRNA was then cut out and inserted into the
NotI site of the pAAV2-MCS (Stratagene, San Francisco, CA).
Small scale production of AAV2=U6–shRNA=CMV–EGFP
was conducted based on a previously published protocol (61).
For large productions, the U6–shRNA=CMV–EGFP cassette
was inserted into the NotI site in the pFBGR plasmid and the
AAV2 vector was produced by the Gene Transfer Vector Core
at University of Iowa based on a previously published pro-
tocol (51).
Animals
The high expression line of transgenic mice expressing
human mutant SOD1G93A (19) was purchased from The
Jackson Lab (Bar Harbor, Maine). The mice have been bred to
FVB background for >10 generations and identified using
PCR as described previously (21). Animals were housed in a
standard environment with 12=12 light cycle. All animal
procedures were approved by the institutional animal care
FIG. 3. Comparison of motor neuron expression of EGFP
between injection of RAd into gastrocnemius muscle and
into sciatic nerve. Fewer motor neurons express express
EGFP in mouse spinal cord 7 days after injection of RAd
(1.25109 particles) into gastrocnemius muscle (A) com-
pared with the injection of the sciatic nerve (B). Notice
the levels of EGFP in individual motor neurons are also
lower in the muscle-injected spinal cord, compared with
the nerve-injected spinal cord. By the same exposure, in the
nerve-injected spinal cord the motor neurons show bright
fluorescence and visible neurites, whereas in the muscle-
injected spinal cord the motor neurons are dimly labeled and
the neurites are not visible. (C) In another experiment, wide
motor neuron expression of EGFP is observed 5 days after
injection of 108 PFU into sciatic nerve. (D) High magnifica-
tion view of labeled motor neurons in (C). The images are
horizontal longitudinal sections of the spinal cord. In (C) and
(D), only the injected sides are shown. Arrows point to the
boards of lateral spinal cord.
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and use committee (IACUC). For monitoring disease pro-
gression, body weight or rotorod test was conducted as de-
scribed previously (6, 59). The early stage of the disease is
defined by a drop of the mouse body weight of 10% or more
from the peak body weight. The end stage of the disease is
defined by a complete paralysis of any two limbs. In a vast
majority of themice, the hinder limbs are paralyzed before the
fore limbs. Therefore, by this assay a delay in hinder limb
paralysis will result in a delay in the onset of the end stage.
Injection of viral vectors and horseradish peroxidase
conjugated cholera toxin subunit B (HRP-CTB)
Mice were anesthetized with avertin and were placed on a
flat surface. The nerves were exposed at the level of thigh.
Approximately 7ml of RAd or AAV2 (various amounts, see
Results), or 3 ml of HRP-CTB (1mg=ml, List Biological La-
boratories Inc., Campbell, CA) were injected into the nerves
using a 5-ml Hamilton syringe with a 33-gauge needle. The
skin was then sutured closed, and the mice were allowed to
recover on a warm pad. At various times after the injection of
the viral vectors or 3 days after the injection of HRP-CTB,mice
were anesthetized with avertin and transcardiacly perfused
with PBS and then with perfusion buffer (2% paraformalde-
hyde and 0.1% glutaraldehyde in PBS). The spinal cord and
the nerves were removed and postfixed with the perfusion
buffer at 48C.
Histology
Spinal cords were sectioned longitudinally (40 mm thick)
using a vibratome. EGFP signal was observed directly using a
fluorescent microscope. To detect SOD1, the sections were
incubated in blocking solution (5% donkey serum, 0.5% Tri-
ton X-100, and 2% fat-free dry milk in PBS) in room temper-
ature for 30min and then in the blocking solution containing
primary antibody sheep anti-SOD1 (Biodesign, Saco, ME, at
1:300) at 48C overnight. After washing, the sections were in-
cubated with the secondary antibody (rhodamine-conjugated
donkey anti-sheep IgG, Jackson ImmunoResearch, West
Grove, PA, 1:100) for 3 h at room temperature. The SOD1
antibody recognizes both human andmouse SOD1.However,
the human SOD1 is expressed in the transgenic mice at
17 times of the mouse endogenous levels (24). Therefore, the
staining intensity in these mice almost entirely represents
human SOD1. To detect the peroxidase reactivity, the sections
were developed using a diaminobenzidine (DAB) kit (Vector
Laboratories, Inc., Burlingame, CA).
Statistical analysis
Two-way ANOVA was used to compare the weight
changes between the RAd-RNAi injected and the RAd-blank
injected animals. Wilcoxon Rank Sum test was used to com-
pare the survival between these two groups of animals.
Results
Efficient delivery of RAd and AAV2 to motor
neurons by nerve injection
We reasoned that injection of viral vectors directly into the
large nerve trunks such as the sciatic nerve can expose the
virus to a large number of axons, and therefore, has the po-
tential to deliver the transgene to the largest population of
motor neurons through a single injection (Fig. 2C). To deter-
mine whether this is true, we prepared a batch of RAd car-
rying an EGFP gene (CMV-EGFP) and injected it into
gastrocnemius muscle and sciatic nerve in equal doses
(1.25109 particles). We observed expression of EGFP in rel-
atively few spinal cord motor neurons after muscle injection
(Fig. 3A). In contrast, in the sciatic nerve injected animal, we
observed a large number of EGFP expressing motor neurons
(Fig. 3B). In some injections, motor neurons expressed EGFP
in a long segment of the lateral motor column, which covered
an area as long as*3.6mm (Fig. 3C and D). This observation
confirms our hypothesis that nerve injection is more efficient
in delivering viral vectors to motor neurons than the muscle
injection.
FIG. 4. EGFP expression in
spinal motor neurons by ret-
rograde transport following
sciatic nerve injection of
AAV2. (A) Three weeks after
injection of AAV2=CMV-
EGFP. (B) A large magnifica-
tion view of the boxed area in
(A). Notice that besides the
brightly labeled neurons, there
are also many weakly labeled
motor neurons in the ventral
horn area. Similar strongly and
weakly labeled EGFP-positive
axons can be observed in the
sciatic nerve: (C) a segment
above the injection site, (D)
a segment at the injection site,
(E) a segment below the injec-
tion site. (F) A sciatic nerve
segment taken from the unin-
jected sciatic nerve from the
same animal.
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To determine whether the nerve injection of AAV is also
more efficient than muscle injection, we tested AAV2, which
was shown previously to be retrogradely transported and to
mediate transgene expression in motor neurons (26). We in-
jected AAV2 (5108) into the gastrocnemius muscle or the
sciatic nerve. At 2–3 weeks after the muscle injection, we
could not find EGFP expressing neurons in the spinal cord
(data not shown). This lack of EGFP-expressing neurons
after muscle injection was most likely caused by the low
viral particle number that we injected, as a minimum of 109
viral particles is required to see the transduced motor
neurons in the spinal cord (26). However, we were able to
readily find many EGFP-expressing motor neurons in the
spinal cord after the nerve injection (Fig. 4). Based on the
successful labeling of motor neurons through nerve injec-
tion but not the muscle injection, together with the data
from the RAd (Fig. 3), we conclude that nerve injection is
superior to muscle injection in delivering RAd and AAV2
to spinal motor neurons.
RNAi delivered by RAd through nerve injection
can mediate silencing of SOD1 in mouse spinal cords
To test whether nerve injection of RAd can be used to ad-
minister RNAi therapy for ALS, we inserted a transgene that
drives the expression of an shRNA against human SOD1 by
the U6 promoter (U6–shR–SOD1a) (60) into the RAd vector
that also expresses EGFP (Fig. 5A). Therefore, this RAd=U6–
shR–SOD1=CMV–EGFP vector expresses both shR-SOD1 for
silencing mutant SOD1 and EGFP for monitoring motor
neuron transduction. As a control, we also constructed a
RAd=U6–blank=CMV–EGFP vector, which expresses EGFP
only. We tested these vectors by infecting cultured HEK293
cells transfectedwith amyc-tagged human SOD1. ByWestern
blot analysis, we found that the vector knocked down both the
transfected and the endogenous SOD1, as reported previously
(60) (data not shown). To test the silencing activity of the
vector in vivo, we injected these vectors into sciatic nerves of
mutant SOD1G93A transgenic mice. Seven days after vector
delivery, we dissected the lower lumbar spinal cord on the
injected side and extracted proteins. ByWestern blot analysis,
we did not detect knockdown of SOD1 (data not shown). This
was not surprising since the shRNA was only expressed in
motor neurons. To specifically examine motor neurons, we
stained for SOD1 signal in the spinal cord sections using im-
munofluorescence.We observed robust expression of EGFP in
motor neurons in the injected side of the spinal cord (Fig. 5B).
Furthermore, in mice injected with RAd=U6–shR–SOD1=
CMV–EGFP, EGFP-expressing motor neurons are correlated
with lowered SOD1 staining (Fig. 5C–E, arrows), in contrast to
the motor neurons without EGFP expression, which dis-
played strong SOD1 staining (Fig. 5C–E, arrowheads). A mi-
nority of themotor neurons expressed EGFP but did not show
strongly decreased SOD1 staining (Fig. 5C–E, open arrows).
This could be caused by a low U6 promoter activity in some
cells because the shRNA and EGFP are driven by independent
promoters.
In contrast to the RAd=U6–shR–SOD1=CMV–EGFP in-
jected animals, we did not find that EGFP-expressing motor
neurons in RAd=U6–blank=CMV–EGFP injected animals
FIG. 5. RAd-delivered RNAi can knockdown mutant SOD1 level in motor neurons. (A) The shRNA- and GFP-expression
cassette that is placed in RAd. U6 and CMV promoters direct synthesis of shRNA against SOD1 and EGFP, respectively. ‘‘T’’
indicates the Pol III transcription termination sequence. ‘‘pA’’ indicates the poly A signal. (B) Robust expression of EGFP in motor
neurons 7 days after injection of the RAd=U6-hSOD1hp=CMV-EGFP into the right sciatic nerve. Red represents SOD1 staining. (C
andD) Themajority of the EGFP expressing neurons (arrows) have lowered SOD1 staining.Motor neurons that do not express EGFP
(arrowheads) have high SOD1 staining. (F–H) A control mouse injected with RAd=U6-SCRAMBLEhp=CMV-EGFP shows EGFP
expression in motor neurons (arrows) but no reduced levels of SOD1. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article at www.liebertonline.com=ars).
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have lowered SOD1 expression (Fig. 5F–H, arrows). Thus, the
lowered mutant SOD1 levels in RAd=U6–shR-SOD1=CMV–
EGFP injected animals are caused by the specific silencing
mediated by the shRNA against SOD1.
Nerve injection of RAd caused inflammation
but did not affect the general motor function
To determine howmuch injury nerve injections cause to the
nerve, we injected the right sciatic nerve ofwild-typemicewith
RAd=CMV–EGFP and sacrificed the animals 1 week after
the injection. Examination of the injected segment showed an
increased cell (macrophage and lymphocyte) infiltration (Fig.
6A) compared with the uninjected side (Fig. 6B), indicating the
presence of inflammation. This is not surprising since the first
generation of RAd is known to cause inflammation. To deter-
mine whether nerve injection caused local motor defects, we
carried out an experiment to assess the effect of RAd injection
on motor function. We divided 8 SOD1G93A animals (68 days
old) into two groups and trained them for a rotorod test twice
weekly for two and half weeks.We then injected RAd into both
sciatic nerves in four animals. We skipped one rotorod test
following the operation to let the mice recover from thewound
and then tested them for another 3 weeks. The four injected
animals performed comparably with the four nonoperated an-
imals (Fig. 6C). This result suggests that RAd injection did not
accelerate motor neuron degeneration and will not interfere
with our observation on the disease progression after the nerve
injection. This was also consistent with our previous observa-
tion that axotomy (a more severe injury than viral injection)
does not accelerate motor neuron degeneration (30) and the
well-established observation that rodents tolerate the first
generation RAd well.
RNAi delivered by RAd, but not by AAV2, through
nerve injection at the disease onset extends
the survival of SOD1G93A transgenic mice
Based on the above observations, we conducted a thera-
peutic trial using RAd=U6–shR–SOD1=CMV–EGFP. We in-
jected this vector into both sides of each animal at 94 days of
FIG. 6. The effect of RAd injection on the sciatic nerve.
(A) Hematoxylin and Eosin (H&E) stained section from the
injected segment of the sciatic nerve. (B) A section from the
uninjected side. (C) Rotorod test of G93A animals before and
after injection of RAd to both sciatic nerves. ‘‘inj’’, injected
group; ‘‘n-op’’, nonoperated group. The date at which the
injected group was operated on was day 0. One test was
skipped after the injection to avoid possible aggravation of
the operation wounds. (For interpretation of the references to
color in this figure legend, the reader is referred to the web
version of this article at www.liebertonline.com=ars).
FIG. 7. RAd-delivered RNAi slows disease progression
and extends survival of SOD1G93A mice. (A) Six pairs of
female SOD1G93A littermates were divided into two groups.
One was injected with RAd expressing shRNA against SOD1
and EGFP and the other was injected with RAd expressing
EGFP alone. The animals were all injected at 94 days of age
(arrow) and weighed before and after the injection. The av-
erage weight changes are plotted. Error bars represent
standard error. We compared the weight and its changes
over time (including times before and after viral injection)
between the two groups using two-way ANOVA. There was
no significant difference between the weights of the two
groups (F¼ 1.6; p¼ 0.21). However, there was a significant
difference in the weight changes over time during aging
between the two groups (F¼ 1.8; p¼ 0.04). There was no
significant interaction between the weight of the mice and
the weight changes over time (F¼ 1.5; p¼ 0.09). (B) Animals
injected with RAd expressing the shRNA lived significantly
longer than those injected with the control RAd (Wilcoxon
rank sum test, p¼ 0.022). (For interpretation of the references
to color in this figure legend, the reader is referred to the web
version of this article at www.liebertonline.com=ars).
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age, which is an average age of disease onset for our mouse
colony based on the peak weight measurement. The control
group was the littermates injected with RAd=U6–blank=
CMV–EGFP. We assessed the disease progression by the
changes in the animals’ body weight (6). On average, the
control group continued to lose weight after the viral ad-
ministration whereas the experimental group gained weight
and this trend of change is statistically significant (Fig. 7A),
suggesting that the disease progression has been slowed.
Confirming the slowing of the disease progression, we ob-
served an extension of survival in the experimental group
(143 6 days) compared with the control group (133 10
days) (Fig. 7B). These data suggest that knockdown of mutant
SOD1 expression in themotor neurons at the disease onset can
slow the disease progression. This result confirms our other
knockdown experiment where a chemically stabilized siRNA
were infused into the spinal cord at the disease onset (54).
These therapeutic effects observed using the RAd vector
are encouraging and demonstrate that nerve injection of the
retrogradely transportable viral vectors can be an efficient
way of delivering RNAi therapy for ALS. However, two
limitations prevented us from gaining an even more robust
therapeutic efficacy. First, the RAd-delivered transgene ex-
pression was only transient. By a longitudinal examination of
the expression levels of EGFP at various times after the RAd
administration, we found that the EGPF level peaked at *1
week after the RAd injection and gradually declined to only a
few scattered motor neurons persistently expressing EGFP in
the following 2 weeks (data not shown). Second, only the
sciatic nerve was injected in this experiment. Future efforts
using the improved versions of RAd (e.g., the gutless RAd)
and injection of other nerves that contain axons from impor-
tant motor neuron pools (see below) may lead to persistent
expression of the shRNA and an enhancement of the thera-
peutic efficacy.
To determine whether using AAV2 to deliver RNAi can
also yield therapeutic efficacy, we tested therapy using the
sameU6–shRNA andCMV–EGFP construct packaged into an
AAV2 vector (AAV2=U6–shR-SOD1=CMV–EGFP). Similar
to the RAd vector, we also tested this vector in cultured cells
and determined it had silencing activity (data not shown). In
our preliminary tests in vivo, we found that AAV2-mediated
expression of EGFP persisted for at least 3 months after the
initial vector injection and that freshly prepared viral particles
worked much better than the frozen viral particles in trans-
ducing motor neurons by nerve injection (data not shown).
We divided SOD1G93A mouse littermates at various ages
into an experimental group and a control group and admin-
istered the AAV2=U6–shR-SOD1=CMV–EGFP to the experi-
mental group.We found no significant difference between the
treated and the control groups in survival (Fig. 8A). Because
the animals in the experimental group were injected at dif-
ferent ages, we also analyzed whether the injection age af-
fected the survival outcome. We found no significant
relationship between the injection age and the survival out-
come (Fig. 8B). Given the persistent transgene expression
mediated by the AAV2 vector, the absence of therapeutic ef-
ficacy is surprising. It might be caused by fewer motor neu-
rons being transduced because overall we observed that
AAV2 transduced fewer motor neurons than the RAd. An-
other potential problem is an insufficient expression of the
shRNA to knockdown the extremely high levels of expression
of mutant SOD1 in this transgenic mouse model. Indeed,
when we examined the SOD1G93A expression in four
AAV2=U6–shR-SOD1=CMV–EGFP-injected mice using the
same immunofluorescence technique as shown in Fig. 5, we
could not find a significant difference between the EGFP-
positive cells and the EGFP-negative cells in their SOD1
staining intensity (data not shown). Thus, further improve-
ment of delivering RNAi using AAV may need to focus on
enhancing transduction efficiency and the RNAi efficacy.
The general practicality of the nerve-injection method
The above data establish that nerve injection is an effective
method for delivering AAV and RAd to spinal cord motor
neurons. Is the nerve injection practical in other nerves? Un-
derstanding this is important because knockdown of mutant
SOD1 in several important motor neuron pools, including
those that innervate the upper limbs, and probably most im-
portantly, those that innervate the respiratory muscles, may
further enhance the efficacy of RNAi therapy. To test this, we
injected the retrograde tracer HRP-ChTxB (1) to variousmajor
FIG. 8. AAV2-delivered RNAi has no effect on the dis-
ease progression in SOD1G93A mice. (A) Female SOD1-
G93A mice were divided into two groups: one injected with
AAV2 expressing shRNA against SOD1 (n¼ 23) and EGFP,
and the other was untreated (n¼ 21). The AAV2 was injected
into the sciatic nerve in mice at ages from 43 days to 109 days.
This group survived for 139 12 days. The untreated group
survived for 138 12 days. (B) The correlation between the
AAV2-injection age and survival was not statistically signifi-
cant ( p¼ 0.2), indicating the age of AAV2 administration did
not affect survival. (For interpretation of the references to color
in this figure legend, the reader is referred to the web version
of this article at www.liebertonline.com=ars).
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nerve trunks before they branch into smaller branches. The
advantages of this approach are that injection of the large
nerves is relatively easy and can expose the injected agent to
more motor axons so that the delivery efficiency can be en-
hanced. In addition to the sciatic nerve, we tested saphenous
nerve, accessible from the ventral side of the upper thigh; the
fore limb major nerves including musculospiral, median and
ulnar nerves, easily accessible from the axilla; and the phrenic
nerve, accessible from the C5 nerve roots. The phrenic nerve
innervates the diaphragm and contains axons from the most
important motor neuron pool that control breathing. Two to
three days after the injection, we fixed the animal by perfusion
and detected HRP labeling using DAB. We observed robust
labeling of these motor neuron pools (Fig. 9A–D), suggesting
that nerves are also accessible for injection of viral vectors.
Discussion
Our results demonstrate that administration of RAd and
AAV2 by nerve injection efficiently delivers transgenes to
spinal cord motor neurons. In addition, incorporation of
RNAi-expression cassette in RAd can elicit gene silencing in
these cells. When we administered RAd carrying the RNAi
cassette against mutant SOD1 to the G93A transgenic mice at
the disease onset, the disease progression was slowed and the
survival extended. These results suggest that delivery of
RNAi using gene therapy through nerve injection can be an
effective therapeutic strategy.
Our study also indicates that further studies are necessary
to enhance the RNAi therapeutic efficacy. The therapeutic
efficacy that we have observed with RAd-RNAi vector is
modest. This probably resulted from the transient expres-
sion mediated by this vector since we have observed that
the expression of EGFP peaked at 1 week after the RAd
administration, and thereafter, the expression declined and
only few motor neurons maintained a sustained expression.
Therefore, future experiments should focus on solving this
problem by using the new generation of RAd vectors. The
recently developed helper dependent gutless adenoviral
vectors (HC-Ad), for example, have been demonstrated to
have low toxicity and the capacity of maintaining a sustained
high level expression of transgenes in the CNS, even in the
presence of a systemic anti-adenoviral immune response
as could be encountered in patients undergoing clinical trials
(4, 29, 49, 62).
AAV has been increasingly used for gene deliveries in vivo
because of its low toxicity and its capability to mediate long-
term transgene expression. A previous study demonstrated
that AAV2 can be retrogradely transported and mediate
transgene expression in motor neurons after its injection into
muscles (26). We compared nerve injection with muscle injec-
tion of AAV2 and found that nerve injection wasmore efficient
in transductionmotor neurons in the spinal cord. Although the
number of motor neurons transduced by AAV2 and the in-
tensity of EGFP expression appeared somewhat lower than in
motor neurons transduced with RAd, AAV2-mediated trans-
gene expression was sustained for a long period of time. Un-
fortunately, AAV2-RNAi vector administered by nerve
injection did not result in an observable knockdown and
therapeutic benefit. This could be due to the fewer transduced
motor neurons and lower levels of shRNA expression com-
pared with the RAd–RNAi vector. Thus, future studies needs
to focus on further enhancing the efficiency of transducing
motor neurons and silencing the target gene. This may be
achieved by using AAV serotypes that have higher affinity to
motor neurons and by optimizing the shRNA or miRNA se-
quence for target gene silencing. For example, AAV serotypes
1 and 8 have much higher transduction efficiency in the CNS
than rAAV2 (22, 48, 53). These serotypes may be combined
with the self-complementary AAV (scAAV) technique to fur-
ther enhance the neuronal transduction efficiency (22). For the
eventual human application, further advantages may be
gained by using nonhuman AAV serotypes or in vitro evolved
AAV vectors, which can avoid pre-existing immunity against
the human AAVs and have optimized neuronal affinity (52).
Thus, much work remains to bring the viral vector-
delivered RNAi therapy for ALS to the clinic. While progress
will be made in this front, an alternative strategy is to deliver
RNAi therapy by directly infusing synthetic siRNA into the
CNS. Several groups have tested this strategy using different
neurodegenerative disease models, including models for
Huntington disease, Parkinson disease, and ALS (15, 31, 54).
These experiments have shown that the infused siRNA can
knockdown the expression of the target disease genes such as
FIG. 9. Large nerve trunks are accessible for injections. (A) Motor neuron pool labeled by injection of HRP–ChTxB into the
cervical VIII nerve. (B) Enlarged view of an area in (A). (C) Motor neuron pool labeled by injection into the saphenous nerve
in lumbar spinal cord. (D) Motor neurons labeled by injection into the cervical V nerve.
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mutant huntingtin, a-synuclein, and SOD1, and in some cases,
display modest therapeutic efficacy. An important feature of
these works is the use of chemically modified siRNA, which
has enhanced stability and cell penetration properties. Com-
pared with the delivery using viral vectors, direct siRNA in-
fusion has the advantage of being able to control the dose of
the siRNA, which enables better control of any possible ad-
verse effects. Other advantages associated with the chemical
modifications include application of special modifications
that can enhance RNAi efficiency against specific disease
targets, reduce the effects of the siRNA on nonspecific targets.
and minimize the siRNA’s immunogenic properties and in-
terference with the endogenous miRNA pathways (56). The
disadvantage of this strategy is that the patient has to carry the
infusion device and the siRNA has to be administered con-
tinuously for life, adding to the cost and inconvenience.
In summary, data from our studies and from other labs
have demonstrated in principle that RNAi can be delivered
using viral vectors expressing shRNAs or chemically modi-
fied siRNAs to treat ALS and other neurodegenerative dis-
orders. For ALS, nerve injection can be a highly effective way
to deliver RNAi-expressing viral vectors into spinal cord
motor neurons. Critical issues still to be addressed are further
enhancing the delivery efficiency using improved viral vec-
tors that have a low or no toxicity and the capability of sus-
taining target gene silencing for a long term. Alternatively,
RNAi may be delivered using chemically modified siRNA.
The critical issues in this approach are to further improve
cellular uptake, to enhance RNAi efficacy, and to reduce off-
target and toxic effects. With persistent efforts, clinical ap-
plication of RNAi therapy is hopeful in the near future.
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